Patent · US Active

Expression and use of anti-CD20 Antibodies

US7744877B2 · kind B2 · utility

18Cited by
32References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 11, 2002
Grant dateJun 29, 2010
Priority date
Expiry dateApr 18, 2029

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/867
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.